Qiming Healthcare — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
WindMIL Therapeutics is a clinical-stage biotechnology company developing cell-based immuno-oncology therapies using marrow-infiltrating lymphocytes (MILs), T cells extracted from a cancer patient's bone marrow that are activated and expanded before being returned to the patient.
BiotechMedical DevicesPrinceton, US
Ivan Borrello(Founder)Kimberly Noonan(Founder)in
BoardBrian Halak(Executive Officer, Director)
Board seatAnna FrenchMark McDade· per SEC Form D · $5M raise · filed Feb 2021
Co-investorsQiming Venture Partners USA
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.


